Robert W. Carlson, MD, CEO of the National Comprehensive Cancer Network (NCCN), discussed calculating value in cancer care and the dimensions of NCCN's value assessment framework, Evidence Blocks.
Robert W. Carlson, MD, CEO of the National Comprehensive Cancer Network (NCCN), discussed calculating value in cancer care and the dimensions of NCCN's value assessment framework, Evidence Blocks.
Transcript (slightly modified)
Why do we need value calculators and the value discussion in oncology today?
Value in oncology care today is a very important topic because the effectiveness of therapies but also because of the cost—both to society and to the individual patient—of the individual therapies. And so it's a circumstance where it's important to know what the consumer, what the healthcare system is getting in return for the dollar cost that is being spent on cancer care. It's very complicated and providing transparent information either by text, tables, or computer-based calculators is very important.
What are the cornerstones of NCCN's Evidence Blocks?
The NCCN Evidence Blocks are based upon 5 different dimensions of data or decision making. The first is the dimension of efficacy: how effective is the therapy? The second is safety: how safe is it to receive the therapy, what kind of difficulties or toxicities would the patient experience with the therapy? The third is that of data quality and quantity that supports the recommendation. The fourth is the consistency of the information that supports the recommendation. And the fifth is that of affordability and how affordable is the therapy to the medical system or society.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Ways Providers, Payers Can Ensure Biomarker Testing Is Done in Cancer Care
October 18th 2024There is a role for both payers and providers to make small changes that would increase the use of biomarker testing to ensure patients are receiving the appropriate treatment, said Susan Wescott, RPh, MBA, senior director of managed care pharmacy, Mayo Clinic.
Read More